Dosing Guide
Retatrutide Dosing Protocol
Complete Retatrutide dosing guide for the triple hormone agonist (GIP/GLP-1/Glucagon). Learn dosing protocol from 1mg to 12mg for maximum weight loss efficacy.
Dosing Schedule
| Phase | Dose | Duration | Purpose |
|---|---|---|---|
| Initiation | 1mg | Week 1-4 | Tolerance building, minimal side effects |
| Escalation 1 | 2mg | Week 5-8 | Initial therapeutic effect |
| Escalation 2 | 4mg | Week 9-12 | Approximately 10% weight loss expected |
| Escalation 3 | 8mg | Week 13-20 | Approximately 17% weight loss expected |
| Maximum | 12mg | Week 21+ | Approximately 24% weight loss (clinical trial data) |
Administration Instructions
- Weekly subcutaneous injection
- Administer same day each week for consistency
- 20mg vial designed for multi-dose clinic use
- Reconstitute with bacteriostatic water
- Store reconstituted solution refrigerated, use within 28 days
- Allow to reach room temperature before injection
Key Benefits
- Triple mechanism: GIP + GLP-1 + Glucagon receptor activation
- Highest weight loss efficacy observed (up to 24% in Phase 2 trials)
- Increases energy expenditure via glucagon receptor activation
- Enhanced appetite suppression from dual incretin action
- Potential liver fat reduction benefits
- Emerging next-generation treatment option
Safety Notes & Precautions
- Currently in clinical trials; not yet FDA-approved for commercial use
- Higher doses may cause more pronounced GI side effects
- Dose escalation should be supervised by a healthcare provider
- Report any unusual symptoms during treatment
- Not recommended in patients with a history of thyroid cancer
Medical Disclaimer: This dosing guide is for educational purposes only. Individual dosing should be determined by a licensed healthcare provider based on your specific health conditions, medical history, and treatment goals. Never adjust your dosing without consulting your healthcare provider. Side effects should be reported immediately, and dose escalation should only occur under medical supervision.